Abdelaziz Rania R, Elkashef Wagdi F, Said Eman
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Mansoura University, Egypt.
Department of Pathology, Faculty of Medicine, Mansoura University, Egypt.
Int Immunopharmacol. 2016 Nov;40:530-541. doi: 10.1016/j.intimp.2016.10.007. Epub 2016 Oct 18.
Silicosis is a crippling respiratory disorder characterized by massive lung inflammation and fibrosis. The current study provides evidence on the protective potential of tadalafil; a specific phosphodiesterase-5 (PDE-5) inhibitor against experimentally-induced pulmonary silicosis in rats. Silicosis was induced by intranasal instillation of crystalline silica (50mg/rat). Halofuginone hydrobromide; a standard collagen-1 synthesis inhibitor was selected as a reference anti-fibrotic. Daily oral administration of tadalafil (1mg/kg) for 8weeks significantly ameliorated silica-induced pulmonary damage. BALF content of inflammatory cells, lung total protein, MDA, nitrite/nitrate, tumor necrosis factor α (TNFα), transforming growth factor β1 (TGF) and collagen contents significantly declined with concomitant reduction in serum LDH activity; confirming reduction of silica-induced oxidative stress and inflammation. Meanwhile, lung SOD activity and GSH content significantly increased; confirming restoration of anti-oxidant defenses. Immunohistochemical analysis of lung TGF expression was correlated with observed biochemical improvements. There was a significant decline in thickness of the walls of the blood vessels and in macrophages and alveolar septal expression of TGF paralleled with reduction in collagen and extracellular matrix (ECM) components deposition. Ultimately, biochemical and histopathological improvements were accompanied by restoration of normal respiratory functions and reduction in airway hyperactivity and responses to both of carbachol and 5-HT. In conclusion; down-regulation of inflammatory and fibrogenic cytokines expression, restoration of oxidants/antioxidant hemostasis, antioxidant boost and promotion of angiogenesis are implicated in the observed protective effect of tadalafil.
矽肺是一种严重的呼吸系统疾病,其特征为肺部大量炎症和纤维化。当前研究提供了关于他达拉非保护潜力的证据;他达拉非是一种特异性磷酸二酯酶-5(PDE-5)抑制剂,对实验性诱导的大鼠肺矽肺具有保护作用。通过鼻内滴注结晶二氧化硅(50mg/大鼠)诱导矽肺。选择氢溴酸常山酮(一种标准的胶原蛋白-1合成抑制剂)作为参考抗纤维化药物。每日口服他达拉非(1mg/kg),持续8周,可显著改善二氧化硅诱导的肺损伤。炎性细胞的支气管肺泡灌洗液(BALF)含量、肺总蛋白、丙二醛、亚硝酸盐/硝酸盐、肿瘤坏死因子α(TNFα)、转化生长因子β1(TGF)和胶原蛋白含量显著下降,同时血清乳酸脱氢酶(LDH)活性降低;证实二氧化硅诱导的氧化应激和炎症反应减轻。与此同时,肺超氧化物歧化酶(SOD)活性和谷胱甘肽(GSH)含量显著增加;证实抗氧化防御功能得以恢复。肺TGF表达的免疫组织化学分析与观察到的生化改善相关。血管壁厚度以及巨噬细胞和肺泡间隔中TGF的表达显著下降,同时胶原蛋白和细胞外基质(ECM)成分的沉积减少。最终,生化和组织病理学改善伴随着正常呼吸功能的恢复以及气道高反应性降低,对卡巴胆碱和5-羟色胺(5-HT)的反应也降低。总之,炎性和纤维化细胞因子表达的下调、氧化剂/抗氧化剂止血的恢复、抗氧化增强以及血管生成的促进与他达拉非观察到的保护作用有关。